集团介绍自定义
Company Profile
Guangzhou Epigenetic Biotechnology Co., Ltd.
Hong Kong Epibiotek Co., Limited., a wholly owned subsidiary of Guangzhou Epibiotek Co., Limited. Building on the parent company's extensive technological expertise in medical epigenetics, Hong Kong Epibiotek delivers high - quality epigenomics services, data analysis support, and research translation solutions to universities, hospitals, research institutes, and biomedical companies worldwide.
The company aims to advance the application and development of cutting - edge omics technologies in basic research, clinical translation, and biomanufacturing. To date, Epibiotek has collaborated with numerous universities and research institutions, more than 600 Grade A tertiary hospitals, and over 100 enterprises. Its services have supported clients in publishing multiple studies in leading international journals, including Nature, Cell, Cancer Cell, and Molecular Cancer.
Epibiotek's Vision To create an RNA technology roadmap and promote the development and application of RNA technologies. 
Epibiotek's Mission To Bring Life Back to Its Original State of Health
Technology Platform
Epibiotek has established four core sequencing platforms - epigenomics, epitranscriptomics, transcription and regulation, and translatomics - through independent R&D and technology introduction, while also developing China's first epigenomics cloud analysis platform, EpiCloud®.
Core Business
Epigenetic Biological Service System
Epibiotek has introduced multiple high-tech services, including super-enhancer identification, HiChIP, ATAC-seq, meRIP-seq, Ribo-seq, GRO-seq, RIC-seq, GlycoRNA-seq, PANDORA-seq, and phase separation studies.
To date, Epibiotek has served over 400 prestigious clients, including renowned universities, Class III Grade A hospitals, research institutes, and enterprises. Customer research achievements have been published in leading journals such as Nature, Cancer Cell, Nature Cell Biology, Immunity, Nature Biotechnology, Gastroenterology, Circulation, and Blood. The company has also established industry-academia-research collaborations with multiple scientific institutions.
Corporate History
2023-07
Established an Engineered Exosome Technology Platform and initiated the Guangdong Provincial Exosome Diagnostics & Therapeutics Industry Innovation Alliance
2023-02
Established a Synthetic Biology Center and constructed a Molecular Enzyme R&D and Production Platform
2023-01
Awarded the 2022 Guangdong Provincial "Specialized, Sophisticated, Distinctive, and Innovative" SME Certification
2022-12
Guangzhou Epigenetic Biotechnology Co., Ltd. was invited to exhibit at the 2022 Global Precision Medicine (China) Summit - Guangzhou Station.
2022-12
The team of Zhang Qi and Xu Yan from the Third Affiliated Hospital of Sun Yat-sen University published research findings on m6A modification and liver fibrosis in Molecular Therapy, and Epigenetic Biotechnology provided meRIP-seq technical services in this study.
2022-12
Received the 2022 Guangdong Province Innovative Small and Medium-sized Enterprise Evaluation and Recognition as a Specialized, Fine, Unique, and Innovative SME.
2022-11
Introduced targeted sequencing of cfDNA methylation, EM-seq, to aid in the development of liquid biopsy biomarkers.
2022-11
Received the Excellence Award in the Growth Group of the 11th China Innovation and Entrepreneurship Competition (Guangdong · Guangzhou Division) and the 2022 Guangzhou Science and Technology Innovation and Entrepreneurship Competition.
2022-10
From October 19th to November 16th, in collaboration with BioArt and the Tumor Marker Committee of the Chinese Anti-Cancer Association, they jointly hosted the "2022 Epigenetics Frontier Theory and Method Series of Special Lectures," consisting of 11 lectures, with over 100,000 participants.
2022-10
Dr. Weng Hengyu from Guangzhou Laboratory, Professor Chen Jianjun from City of Hope in the United States, Dr. Huang Huilin from Sun Yat-sen University Cancer Center, and Professor Wei Minjie from China Medical University collaborated to publish research findings related to Acute Myeloid Leukemia (AML) in Cancer Cell, and Epigenetic Biotechnology provided Ribo-seq sequencing technical services in this study.
2022-9
Developed the tRNA m7G modification sequencing technology TRAC-seq, which can achieve single-base resolution.
2022-8
Established a "Joint Epigenomics Laboratory" with Shanghai Maiqi Biotechnology to better serve customers in the East China region.
2022-7
Invited to participate in the 8th National Conference on Computational Biology and Bioinformatics (NCCBB).
2022-6
The technical lecture "Super Enhancer Research Topic Design and Application of Related Sequencing Technologies" was live-streamed on the Epigenetic Biotechnology video channel, and the lecture allowed participants to gain a deeper understanding of super enhancer research.
2022-5
The technical lecture "Application of Pandora Sequencing Technology in the Study of Non-coding Small RNAs" was broadcast on the Epigenetic Biotechnology video channel, attracting many researchers in this field to watch.
2022-5
Established a "Joint Laboratory of Tumor Epigenetics" with LeYou Biotechnology to promote research on tumor mechanisms and the development of new drug targets.
2022-4
Upgraded the CUT&Tag library construction method to enhance data accuracy and reduce background noise.
2022-1
Professor Liu Chunxiao's team from the Zhujiang Hospital of Southern Medical University published research findings related to NAT10 and bladder cancer in Clinical and Translational Medicine, and Epigenetic Biotechnology provided acRIP-seq technical services in this study.
2021-12
Further improved the direct sales network by adding four new sales offices in Chongqing, Beijing, Shenyang, and Wuhan throughout the year, to better serve local customers.
2021-12
Successfully selected as a "Specialized, Fine, Unique, and Innovative" enterprise in Guangzhou in 2021.
2021-11
Invited to exhibit at the 6th Epigenetics and Biopharmaceutical R&D Academic Conference, showcasing the company's latest epigenetic drug target screening technology.
2021-11
Invited to exhibit at the 5th National Extracellular Vesicle Conference, the company's latest liquid biopsy technology HEBER-seq attracted attention.
2021-10
Collaboratively introduced the KeyGene IPA (Ingenuity Pathway Analysis) platform to enhance the analysis of regulatory networks, promote target screening, and facilitate the discovery of biomarkers.
2021-8
Successfully developed the PANDORA-seq technology for sequencing modified small RNAs.
2021-6
The invention patent "A Method for Rapid Construction of Transcriptome Sequencing Library and Its Application" was authorized by the China National Intellectual Property Administration.
2021-5
Successfully developed the CROP-seq technology, which perfectly combines CRISPR screening with single-cell transcriptome sequencing.
2021-1
Invited to exhibit at the 2nd National RNA Youth Academic Conference.
2019-12-28
Successfully held the third Epigenetic Biotechnology Special Workshop with the theme of RNA Modification Research and Preparing for the 2020 NSFC, with 139 participants.
2019-12-03
After a rigorous assessment, Epigenetic Biotechnology was recognized as a High-tech Enterprise.
2019-11-10
Held the second Epigenetics Special Workshop with the theme of enhancers and higher-order chromatin structure, with 123 participants.
2019-10-28
The R&D department of Epigenetic Biotechnology has established the HiChIP and Hi-C library construction techniques.
2019-10-18
Invited to participate in the 3rd National Extracellular Vesicle Conference (CSEV) in Xi'an in 2019.
2019-10-09
The Ribo-seq library construction technology has been fully upgraded to achieve higher library construction efficiency and obtain higher quality sequencing data.
2019-07-06
Epigenetic Biotechnology successfully held its first epigenetics-focused workshop, with the theme of RNA modification research. The instructors included Dr. Lin Shuibin from Sun Yat-sen University, Dr. Zhou Keren from Sun Yat-sen University, and Dr. Wang Zelin, the Bioinformatics Technical Director of Epigenetic Biotechnology. There were 139 participants in the workshop.
2019-03-19
Epigenetic Biotechnology successfully held a three-day second edition of the Advanced Medical Epigenetics Technology Training Course. The instructors included Dr. Xin Liu from the University of Texas Southwestern Medical Center, Dr. Lin Shuibin from Sun Yat-sen University, Dr. Huang Shengli from Fudan University, Dr. Zhang Qiangfeng from Tsinghua University, and Professor Yang Jianhua from Sun Yat-sen University. There were 128 participants in the training course.
2019-01-15
Dr. Wang Zelin joined Epigenetic Biotechnology as the Director of Bioinformatics, initiating the upgrade and construction of the epigenomics bioinformatics platform.
2019-01-05
Epigenetic Biotechnology joined the second Innovation Technology and Evaluation Group of the Clinical Medicine Branch of the China Medical Equipment Association.
2018-09-09
Successfully established the Epigenetic Medicine Cloud Platform.
2018-01-18
Launched exosomal small RNA sequencing service, capable of simultaneously detecting miRNA, tsRNA, and piRNA.
2017-03-11
Became the first to offer exosomal longRNA-seq service, capable of simultaneously detecting exosomal mRNA, lncRNA, and circRNA molecules.
2023-06
Launched DNA Methylation Sequencing Technologies: WGBS (Whole-Genome Bisulfite Sequencing), RRBS (Reduced Representation Bisulfite Sequencing), and TBS (Targeted Bisulfite Sequencing)
2023-01
Launched Active Ribo-seq (Active Ribosome Profiling Sequencing) Technology
2022-12
Guangzhou Epigenetic Biotechnology Co., Ltd. was invited to participate in the 2022 Frontiers of Basic and Translational Research in Oncology Symposium.
2022-12
The research team of Wang Bin from the Guangdong Provincial Institute of Intelligence and the research team of Bao Lan from the Chinese Academy of Sciences Molecular Cell Excellence Center have published research findings in Cell Reports, and Epibiology provided a SELECT-m6A modification unit quantitative detection kit in this study.
2022-12
Once again, it has been recognized as a National High-tech Enterprise.
2022-11
Professors Yang Ye and Gu Chunyan from Nanjing University of Chinese Medicine published research findings related to NAT10 and multiple myeloma in Acta Pharmaceutica Sinica B, and Epigenetic Biotechnology provided acRIP-seq and Ribo-seq technical services in this study.
2022-11
Professor Liu Qinghuai and Associate Professor Chen Xue's research team from the First Affiliated Hospital of Nanjing Medical University published research findings on the relationship between m6A modification and age-related macular degeneration in Cell Reports, and Epigenetic Biotechnology provided the SELECT-m6A modification unit point quantitative detection kit in this study.
2022-10
Signed an agreement to introduce the Qsep400 high-throughput nucleic acid protein analysis system from Qsep, accelerating the delivery of sequencing projects and the development of new technologies.
2022-10
Professor You Han's team from Xiamen University published research findings related to METTL3 and tumor metastasis in Nature Communications, and Epigenetic Biotechnology provided meRIP-seq technical services in this study.
2022-9
The live course "RNA Modification Research Topic Design and Application of the Latest Sequencing Technologies" was launched on the Epigenetic Biotechnology public account, where the lecturer provided a detailed explanation of the research design approach in this field.
2022-9
Developed the tRNA m7G modification sequencing technology TRAC-seq, which can achieve single-base resolution.
2022-7
Held a company strategy seminar on "Process and Performance" to promote continuous upgrading of corporate organizational processes and efficiency improvement.
2022-6
Signed an agreement to join the Leading Research Society, systematically introduced corporate management courses, and built a learning organization within the enterprise.
2022-6
The lecture "RNA modifications in gene expression regulation," hosted by BioArt, exclusively sponsored by Epigenetic Biotechnology, and presented by researcher He Chuan, was successfully held with over 20,000 participants.
2022-5
Professor Su Peiqiang's team from the First Affiliated Hospital of Sun Yat-sen University published the latest research findings on intervertebral disc degeneration in Molecular Therapy, and Epigenetic Biotechnology provided ATAC-seq technical services in this study.
2022-3
Introduced the EpiTM DRUG-seq technology to advance drug screening research.
2022-3
The research team led by You Bo from the Affiliated Hospital of Nantong University published research findings related to PGCC cells and nasopharyngeal carcinoma in Cancer Research, and Epigenetic Biotechnology provided ATAC-seq technical services in this study.
2022-1
Professors Yang Ye and Gu Chunyan from Nanjing University of Chinese Medicine published research findings related to NAT10 and multiple myeloma in Acta Pharmaceutica Sinica B, and Epigenetic Biotechnology provided acRIP-seq and Ribo-seq technical services in this study.
2021-12
Completed the development of the AIXELLOM single-cell sequencing platform with independent intellectual property rights and submitted multiple patent technology applications.
2021-11
Held the 5th anniversary celebration, and colleagues including Chen Yongshun received the "5th Anniversary Honorary Medal" and commemorative gifts.
2021-11
Completed the expansion and upgrade of the laboratory to meet the rapidly growing demand of the sequencing service market.
2021-10
Hosted the 2021 Epigenetic Biotechnology Special Online Workshop, with 16 distinguished lecturers, live-streamed on platforms such as Xiaohetong, WeChat Video Account, and Bilibili, with an audience of over 20,000 people.
2021-9
Obtained the successful transformation authorization of the SELECT-m6A quantitative detection technology from Peking University, promoting the development of epitranscriptomic research.
2021-7
Invited to participate in the 11th National RNA Conference, showcasing solutions for m6A modification research.
2021-6
Obtained the transformation authorization of the RIC-seq technology from the Chinese Academy of Sciences at the Nature level, promoting research on RNA interaction networks and higher-order structures.
2021-3
Launched the 2021-2022 edition of the Medical Epigenetics Research Technology and Solution Manual.
2019-12-31
The construction of the Epigenetic Biotechnology Single-Cell Sequencing Technology Collaborative Innovation Center was officially launched.
2019-12-16
Epigenetic Biotechnology was recognized as a Gazelle Enterprise by the Huangpu District of Guangzhou.
2019-11-25
Officially launched the RNA metabolism research technology SLAM-seq sequencing project.
2019-10-29
Epigenetic Biotechnology obtained a total loan credit of 5 million from the Bank of China.
2019-10-21
Epigenetic Biotechnology collaborates with Huawei Cloud to initiate the construction of the "Epigenetic Medicine Public Cloud" bioinformatics platform.
2019-10-10
The epigenetic information system platform went live, achieving full-process management for the enterprise.
2019-08-30
Epigenetic Biotechnology won the Excellence Award in the Growth Group of the 8th China Innovation and Entrepreneurship Competition (Guangdong · Guangzhou Division) and the 4th Yangcheng "Science and Innovation Cup" Innovation and Entrepreneurship Competition.
2019-05-11
Epigenetic Biotechnology was invited to participate in the 1st National RNA Youth Academic Conference in Beijing.
2019-03-18
Epigenetic Biotechnology was the first in China to launch the acRIP-seq service for RNA acetylation sequencing.
2019-01-10
Epigenetic Biotechnology was the first in China to introduce the ultra-low input meRIP-seq sequencing technology, promoting research in the epigenetic transcriptome.
2018-10-12
Held the inaugural Medical Epigenetics Frontier Technology Training Course.
2018-04-21
Passed the Intellectual Property Management System Certification.
2017-08-25
Launched super enhancer identification service and comprehensive research solutions.
2016-11-05
Epigenetic Biotechnology was officially registered and established.
Cultural and Social Activities
Selected Partner Organizations